Ovarian Cancer
Merck KGaA, Hengrui Pharmaceuticals Ink Oncology Drug Licensing Deal Potentially Worth $1.48B
Merck KGaA gained exclusive rights to Hengrui's PARP inhibitor HRS-1167 and an option for exclusive rights to its CLDN18.2 antibody-drug conjugate SHR-A1904.
Relay Therapeutics Seeks Tumor-Agnostic Market for FGFR2 Inhibitor Citing Medicare Pricing Pressures
Premium
Positive data from the ReFocus trial has prompted the firm to shift from a strategy for lirafugratinib in rare bile duct cancer to a broader pan-tumor approach.
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
The Invitae Common Hereditary Cancers Panel is the first test of its kind to obtain FDA marketing authorization, creating an easier pathway for similar tests.
The funds will allow Rice University researchers to build a functional prototype of THOR, a device that senses tumor growth and manufactures drugs to treat cancers in real time.
ImmunoGen to Share Data With Regulators Showing Elahere Benefit Across Ovarian Cancer Subgroups
Elahere benefited patients with FRα-positive ovarian cancer regardless of how many prior treatments they had received and if they had received a PARP inhibitor.